NCT03959085 2026-03-31
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Children's Oncology Group
Phase 3 Recruiting
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
AIDS Malignancy Consortium
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group
Children's Oncology Group